

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/54, 9/12, A61K 38/45, 9/127, C12N 5/08, A23L 1/00 // A61P 35/00		A2	(11) International Publication Number: WO 00/61766 (43) International Publication Date: 19 October 2000 (19.10.00)
(21) International Application Number: PCT/IB00/00610 (22) International Filing Date: 7 April 2000 (07.04.00) (30) Priority Data: 60/128,539 9 April 1999 (09.04.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/128,539 (CIP) Filed on 9 April 1999 (09.04.99) (71) Applicant (for all designated States except US): BIOMIRA, INC. [CA/CA]; 2011 - 94th Street, Edmonton, Alberta T6N 1H1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): AGRAWAL, Babita [IN/CA]; 732 Revell Crescent, Edmonton, Alberta T6R 2E8 (CA). LONGENECKER, Bryan, Michael [CA/CA]; 440 Rooney Crescent, Edmonton, Alberta T6R 1C8 (CA). (74) Agent: RUDOLPH, John, R.; BERESKIN & PARR, 40 King Street West, Box 401, Toronto, Ontario M5H 3Y2 (CA).			(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: TELOMERASE-SPECIFIC CANCER VACCINE			
(57) Abstract Telomerase-specific T-cell antigens are provided, which are useful in generating T-cell responses against telomerase. Formulations of telomerase antigens as vaccines are useful in treating and preventing cancer, using <i>in vivo</i> or <i>ex vivo</i> techniques.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon		Republic of Korea	PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

TELOMERASE-SPECIFIC CANCER VACCINE

5

BACKGROUND OF THE INVENTION

Telomeres, the DNA at the chromosome ends, are made up of simple tandem repeats. In most somatic cells, telomere sequences are lost during DNA replication due to the need of DNA-dependent DNA polymerases for an RNA primer annealed to the template strand. Because the RNA primer cannot anneal beyond the 5' end of the DNA strand, each
10 time a cell's DNA replicates, short bits of telomeric DNA are lost with each generation. Cells displaying such telomeric shortening go into senescence after a fixed number of population doublings, and senescence correlates directly with the erosion of telomeres to a critical minimum length.

Not all cells undergo such loss, however. While normal human somatic cells
15 lose telomeric repeats with each cycle of cell division, human germline and, significantly, cancer cells maintain a constant number of telomeric repeats. Telomere length is maintained in these cells by the action of telomerase, a ribonucleoprotein enzyme that uses a short endogenous RNA as a template for telomere addition. In fact, cancer cells express high levels of telomerase, whereas somatic cells express little, if any.

20 Because normal somatic cells do not appear to express or require telomerase, whereas cancer cells express high levels of telomerase, the telomerase enzyme presents an attractive therapeutic target. Due to the fact that telomerase is a normal "self" antigen, however, conventional vaccination strategies are unavailable. Thus, the focus of telomerase-based therapeutics has been enzyme inhibitors of various sorts, rather than vaccine-based
25 approaches.

A need exists, therefore, for new telomerase-based therapeutic approaches. This need extends to vaccines, based on telomerase antigens.

SUMMARY OF THE INVENTION

It is, therefore, an object of the invention to provide antigens that are useful in generating an immune response against telomerase. According to this object of the invention, telomerase antigens are provided that are capable of marshalling the immune system against telomerase-expressing cells. In one embodiment, telomerase antigens are provided, which are based on peptide sequences of the protein portion of telomerase. In another embodiment, telomerase antigens are provided as nucleic acids that are capable of being used to express peptide-based telomerase antigens.

It is another object of the invention to provide vaccine compositions which include at least one telomerase antigen. Thus, in one aspect, the invention provides vaccine compositions containing telomerase peptide antigens. In another aspect, polynucleotides are provided, which encode protein-based telomerase antigens.

It is still another object of the invention to provide methods of treating or preventing cancer. According to this object, the telomerase antigens of the invention may be directly administered in beneficial amounts to a patient. Also according to this object, the present telomerase antigens may be administered to a patient encoded in a nucleic acid. This object is also met by *ex vivo* methods that involve contacting a cell with a telomerase antigen, and administering that cell to a patient. In one aspect, the contacted cell may be an antigen presenting cell, which may be used to generate a primed T-cell *ex vivo*, at which time the primed T-cell may be administered to a patient.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows fluorescence activated cell sorting (FACS) analysis of T-cells activated by telomerase-specific antigens. Panels A and B are negative and positive controls, respectively, and panels C, D and E are antigen candidates.

DETAILED DESCRIPTION

The present invention relates to a telomerase-specific vaccines, which are useful generating telomerase-directed activated T-cells. More particularly the inventive vaccines are useful in generating antigen-specific major histocompatibility- (MHC-) restricted T-cell responses against telomerase presented by antigen presenting cells. It is believed that the present vaccines act to relieve the tolerance or anergy induced through self-tolerance mechanisms to telomerase in normal individuals. Since telomerase represents a cancer-specific therapeutic target, in one embodiment, the vaccines of the invention are useful in the treatment or prevention of a variety of cancers.

10 **A. Definitions**

As used in this specification, an "activated T-cell" is one that is in the following phases of the cell cycle: the G₁ phase, the S phase, the G₂ phase or the M (mitosis) phase. Thus, an "activated T-cell" is undergoing mitosis and/or cell division. An activated T-cell may be a T helper (T_H) cell or a cytotoxic T-cell (cytotoxic T lymphocyte (CTL or T_C)).

15 Activation of a naive T-cell may be initiated by exposure of such a cell to an antigen-presenting cell (APC) (which contains antigen/MHC complexes) and to a molecule such as IL-1, IL-2, IL-12, IL-13, γ -IFN, and similar lymphokines. The antigen/MHC complex interacts with a receptor on the surface of the T-cell (T-cell receptor (TCR)). Golub *et al.*, eds. IMMUNOLOGY: A SYNTHESIS, Chapter 2: "The T-cell Receptor" (1991).

20 As used in this specification, "priming" is used to mean exposing an animal (including a human) or cultured cells to antigen, in a manner that results in activation and/or memory. The generation of CD4⁺ and CD8⁺ T-cell responses against a target antigen is usually dependent upon *in vivo* priming, either through natural infection or through deliberate immunization.

25 As used in this specification, a "naive" T-cell is one that has not been exposed to foreign antigen (non-autologous) antigen or one that has not been exposed to cryptic autologous antigen. A "naive" T-cell is sometimes referred to as an "unprimed" T-cell. The

skilled artisan will recognize that a "resting" cell is in the G_0 phase of the cell cycle and hence is not dividing or undergoing mitosis. The skilled artisan will also recognize that an "anergic" T-cell is one that is unable to function properly; *i.e.*, such as a cell that lacks the ability to mediate the normal immune response. T-cells from diseased patients may contain T-cells that

5 have been primed, but are anergic.

As used in this specification "memory T-cells," also known as "memory phenotype" T-cells, is used to designate a class of T-cells that have previously encountered a peptide antigen but are now resting and are capable of being activated. Memory T-cells are T-cells which have been exposed to antigen and then survive for extended periods in the body

10 without the presence of stimulating antigen. However, these memory T-cells respond to "recall" antigens. In general, memory T-cells are more responsive to a "recall" antigen, when compared with the naive T-cell response to peptide antigen. Memory cells can be recognized by the presence of certain cell-surface antigens, such as CD45R0, CD58, CD11 α , CD29, CD44 and CD26, which are markers for differentiated T-cells.

As used in this specification, an "telomerase-specific" T-cell response is a T-cell response (for example, proliferative, cytotoxic and/or cytokine secretion) to telomerase antigenic stimulus, for example a peptide, which is not evident with other stimuli, such as peptides with different amino acid sequences (control peptides). The responsiveness of the T-cell is measured by assessing the appearance of cell surface molecules that are characteristic

15 of T-cell activation, including, but not limited to CD25 and CD69. Such assays are known in the art.

20

The term "treating" in its various grammatical forms in relation to the present invention refers to preventing, curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of a disease state, disease progression, disease

25 causative agent or other abnormal condition.

B. Telomerase Antigens

1. Generally Useful Antigens

Telomerase antigens according to the invention share the characteristic ability to generate a specific T-cell response. This response may be either class I- or class II-specific.

5 In one aspect, this response is MHC class I-specific, and will comprise antigen- and MHC-restricted cytotoxicity. Class I molecules include HLA-A, HLA-B and HLA-C. Thus, preferred antigens bind class I molecules, *e.g.*, HLA-A1, HLA-A2, HLA-A3 or HLA-A11. More preferred antigens bind all class I molecules. In contrast, where class II-specific (*e.g.*, helper functions) responses are desired, class-II-binding antigens will be used. Class II
10 molecules include HLA-DR, HLA-DQ and HLA-DP. Useful antigens can be determined as set out below.

Telomerase antigens are typically derived from the sequence of the protein portion of telomerase, which is disclosed in U.S. Patent No. 5,837,857 (1998) and at GenBank
Accession Nos. AF015950 and AF018167, which sequences are hereby incorporated by
15 reference. They may be made, for example, by proteolytic digestions of the telomerase protein and/or by recombinant DNA means. Generally, the relatively short peptide versions will be prepared by synthetic means.

Although telomerase antigens according to the invention are not limited by size, and they may be a portion or even all of the telomerase protein, they are usually small
20 peptide antigens. A small size is preferred, due to ease of manufacture and greater specificity. Accordingly, unless they are multimeric (*i.e.*, multiple copies of the same epitope) most telomere antigens will be less than about 50 amino acids in length. Preferred antigens are less than about 25 amino acids in length, with other preferred antigens being between about 8 to about 12 amino acids long, although sequences as short as 6 or 7 amino acids are
25 contemplated. Nine-mers are typical of class I antigens, since they usually retain the requisite functional character; they include Ile-Leu-Ala-Lys-Phe-Leu-His-Trp-Leu (ILAKFLHWL) as a preferred species.

Variants of telomerase antigens are also contemplated. It is only important that any variants retain the functional characteristics of a telomerase antigen: (1) the ability to bind an MHC molecule, *e.g.*, HLA-A2, and (2) the ability to induce a telomerase specific T-cell response. Amino acid substitutions, *i.e.* "conservative substitutions" that yield "conservative variants," may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.

For example: (a) nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positively charged (basic) amino acids include arginine, lysine, and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d). In addition, glycine and proline may be substituted for one another based on their relatively small sizes and lack of side-chains.

Similarly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in α -helices, while valine, isoleucine, phenylalanine, tyrosine, tryptophan and threonine are more commonly found in β -pleated sheets. Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns. The importance of substitution groups based on structure, of course, increases with the length of the antigen.

Some preferred conservative substitutions may be made among the following groups: (i) S and T; (ii) P and G; and (iii) A, V, L and I. Given the known genetic code, and recombinant and synthetic DNA techniques, the skilled scientist readily can construct DNAs encoding the conservative amino acid variants. Of course, smaller variants may be synthesized. One such genus of conservative HLA-A2-binding variants includes peptides of the structure: (A/V/L/I)(A/V/L/I)(A/V/L/I)(A/V L/I)KF(A/V/L/I)HW(A/V/L/I). Thus, some preferred conservative variants include LLAKFLHWL, ILAKFLHWI, IIAKFLHWL,

IIAKFLHWI, ILARFLHWL, and ILVKFLHWL, and permutations thereof, so long as the requisite functional characteristics are retained.

Moreover, one or more of the amino acids of the foregoing HLA-A2-binding peptides may be replaced with glycine. Parker *et al.*, J. Immunol. 149:3580-87 (1992) disclose that up to six amino acids in a nine-mer may be replaced with glycine; thus, GLFGGGGGV can bind HLA-A2. The only real conservation observed in 9-mer HLA-A2-binding peptides was an Ile or a Leu at about position 2 (counting N- to C-terminal) and a Val or a Leu at about position 9. Some simple variants, therefore, include GLAKFLHWL, ILAGFLHWL, ILAKGLHWL, ILAKFGHWL, ILAKFLGWL and ILAKFLHGL, subject to the presence of the requisite functional characteristics.

An important source for guidance in regard to designing class I and class II antigens, and in making conservative substitutions is Rammensee *et al.*, Immunogenetics 41:178-228 (1995), which is hereby incorporated by reference in its entirety. As indicated in the Rammensee reference, the motifs for both class I and class II molecules have certain "anchor" residues, that retain high degrees of conservation. For instance, HLA-A0201 (an HLA-A2 molecule), which is the molecule that the telomerase peptide ILAKFLHWL was designed to bind (and does bind), has anchor residues at positions 2 and 9, corresponding to the conservative positions noted above. This molecule also has an "auxiliary" position at 6, the relative conservation of which is important, but less so than the anchor residues. Thus, using the general guidance of Rammensee, the artisan will appreciate that, while the anchor residues and auxiliary residues are relatively conserved in HLA binding, the remainder of the antigen can vary widely, and is probably responsible for the particular antigenic character of the antigen, *i.e.*, it differentiates telomerase from non-telomerase.

Other substitutions include replacing L-amino acids with the corresponding D-amino acids. This rationale, moreover can be combined with the foregoing conservative substitution rationales. For example, D-leucine may be substituted for L-isoleucine. In addition, these D-amino acid-containing peptides may be prepared which have an inverse sequence, relative to the

native sequence. Hence, ILAKFLHWL becomes LWHLFKALI. Such "retro-inverso" peptides are expected to have improved properties, such as increased *in vivo* half-life. This translates into smaller doses and more economically viable production.

Some embodiments contemplate multimers of the foregoing peptides.

- 5 Multimers can contain multiple copies of the same peptide, or they can be mixed and matched. The multimers can be direct tandem repeats, and may contain short spacers sequences of amino acids (*e.g.*, 2-5 residues) like Gly and/or Pro, or other suitable spacers. Multimers may be any length, but typically will be less than about 100 amino acids. Preferred multimers are less than about 60 amino acids and have between about 2 and 5 copies of
- 10 peptides of about 8 to about 12 amino acids long. Multimers may also comprise several different telomerase antigens.

- The telomerase antigens may be glycosylated or partially glycosylated according to methods known in the art. They also can be modified with large molecular weight polymers, such as polyethylene glycols. In addition, lipid modifications are preferred
- 15 because they may facilitate the encapsulation or interaction of the derivative with liposomes. Exemplary lipid moieties useful for this purpose include, but are not limited to, palmitoyl, myristoyl, stearoyl and decanoyl groups or, more generally, any C₂ to C₃₀ saturated, monounsaturated or polyunsaturated fatty acyl group.

- For convenience in making chemical modifications, it is sometimes useful to
- 20 include in a telomerase antigen one or more amino acids having a side chain amenable to modification. A preferred amino acid is lysine, which may readily be modified at the ϵ -amino group. Side-chain carboxyls of aspartate and glutamate are readily modified, as are serine, threonine and tyrosine hydroxyl groups, the cysteine sulfhydryl group and the histidine amino group. The introduction of two cysteine residues, at spaced locations in a peptide antigen,
- 25 may serve to form a structural constraint through a disulfide bridge, which may improve binding to MHC molecules.

Also illustrative of a telomerase antigen within the present invention is a non-peptide "mimetic," *i.e.*, a compound that mimics one or more functional characteristics of the telomerase antigen. Mimetics are generally water-soluble, resistant to proteolysis, and non-immunogenic. Conformationally restricted, cyclic organic peptides which mimic telomerase
5 antigens can be produced in accordance with known methods described, for example, by Saragovi, *et al.* *Science* 253: 792 (1991).

Telomerase antigens may also be constructed as hybrids (and/or formulated as distinct molecules together in liposomes, as described below) with immune-stimulatory molecules, like cytokines and adjuvants. Interleukin-2 (IL-2) is one such cytokine. Other
10 cytokines include GM-CSF, IL-12 and flt-3 ligand. Telomerase antigens may be made as fusion proteins with IL-2, for example, by recombinant DNA or chemical synthetic means, or they may made as chemical conjugates using bi-functional chemical linkers. It is anticipated that such chimeric proteins would possess an increased ability to generate a T-cell-specific response against telomerase. Adjuvants include monophosphoryl lipid A (MPLA), and
15 derivatives thereof, which also may be attached to a telomerase antigen by conventional linkers. Other conventional immune stimulatory molecules include keyhole limpet hemocyanin (KLH).

2. Identification of Other Useful Antigens

It is of interest to identify additional, and especially small telomerase antigens,
20 which would be expected to generate a more specific response, associated with a particular epitope for example. Moreover, these small antigens may be more economically produced.

It is advantageous to identify additional telomerase antigen and further to refine the T-cell antigenicity of telomerase, even down to the epitopic level. One classic method involves proteolytic treatment of the large antigen to derive smaller antigens. In
25 addition, fragments of protein antigens can be produced by recombinant DNA techniques and

assayed to identify particular epitopes. Moreover, small peptides can be produced by *in vitro* synthetic methods and assayed.

As an alternative to the random approach of making parts of the intact antigen then assaying them, a more biologically relevant approach is possible. Specifically, since
5 antigenic fragments which bind to MHC class I and/or class II molecules, especially class I molecules, are of particular importance, one exemplary approach is to isolate the MHC molecules themselves and then to isolate the peptides associated with them. For a general description of such a method, see PCT/US98/09288; Agrawal *et al.*, Int'l Immunol.10:1907-16 (1998); and Agrawal *et al.*, Cancer Res. 55:5151-56 (1998).

10 In a typical method, either primary tumor cells or a cell line expressing the antigen of interest are provided. In addition, it will be recognized that phagocytic antigen presenting cells (or any APC), such as macrophages, may be fed large antigens (or portions thereof) and thus act as the starting material for these methods. The MHC class I or class II molecules can be isolated from these starting cells using known methods, such as antibody
15 affinity (MHC-specific antibodies) and chromatographic techniques.

Isolated MHC molecules are then treated to release bound peptides. This may be accomplished by treatment with agents that disrupt the interactions between the bound peptide and the MHC molecule, for example, detergent, urea, guanidinium chloride, divalent cations, various salts and extremes in pH. The peptides released can be further purified using
20 conventional chromatographic and antibody affinity (using antigen-specific antibody) methodologies. The purified peptides may then be subjected to sequence and structural determinations, using for example peptide sequencing, gas chromatography and/or mass spectroscopy.

In this manner the sequences, structures of the most prevalent peptide epitopes
25 associated with class I and/or class II molecules may be determined. Supplied with this sequence/structural information, permutations of the determined sequence can be made, as

detailed above, and assayed using known T-cell assays. Rammensee *et al.*, *supra*, provides extensive methods and guidance related to identifying both class I and class II motifs.

Yet another method of generating telomerase antigens may utilize algorithms known in the art for predicting binding sequences. Publicly available comparison programs using these algorithms to compare known peptide sequences to different HLA-binding motifs may be found, for example, at http://www-bimas.dcrn.nih.gov/hla_bind. Different class I and class II binding motifs may be found at that site or in publications like Rammensee *et al.* and Parker *et al.*, both *supra*.

C. Vaccine Compositions

In general, any telomerase-specific antigen, as described above, will be useful in formulating telomerase-specific vaccines. Preferred antigens may be associated with lipids, usually either by direct lipid modification of the antigen and/or by liposomal association, as described below. The antigens may be administered as peptides or peptide mimetics, or they may be administered in nucleic acid form.

1. Liposomal Formulation

In one embodiment of the invention, the telomerase antigen is associated with a liposome. Techniques for preparation of liposomes and the formulation of various molecules, including peptides, with liposomes (*e.g.*, encapsulation or complex formation) are well known to the skilled artisan. Liposomes are microscopic vesicles that consist of one or more lipid bilayers surrounding aqueous compartments. See, generally, Bakker-Woudenberg *et al.*, *Eur. J. Clin. Microbiol. Infect. Dis.* 12 (Suppl. 1): S61 (1993) and Kim, *Drugs* 46: 618 (1993). Liposomes are similar in composition to cellular membranes and as a result, liposomes generally can be administered safely and are biodegradable.

Depending on the method of preparation, liposomes may be unilamellar or multilamellar, and can vary in size with diameters ranging from 0.02 μm to greater than 10 μm . A variety of agents can be encapsulated in liposomes. Hydrophobic agents partition in

the bilayers and hydrophilic agents partition within the inner aqueous space(s). See, for example, Machy *et al.*, LIPOSOMES IN CELL BIOLOGY AND PHARMACOLOGY (John Libbey 1987), and Ostro *et al.*, (1989) *American J. Hosp. Pharm.* 46: 1576.

5 Liposomes can adsorb to virtually any type of cell and then release the encapsulated agent. Alternatively, the liposome fuses with the target cell, whereby the contents of the liposome empty into the target cell. Alternatively, an absorbed liposome may be endocytosed by cells that are phagocytic. Endocytosis is followed by intralysosomal degradation of liposomal lipids and release of the encapsulated agents. Scherphof *et al.*, (1985) *Ann. N.Y. Acad. Sci.* 446: 368.

10 Anionic liposomal vectors have also been examined. These include pH sensitive liposomes which disrupt or fuse with the endosomal membrane following endocytosis and endosome acidification. Among liposome vectors, however, cationic liposomes are the most studied, due to their effectiveness in mediating mammalian cell transfection *in vitro*.

15 Cationic lipids are not found in nature and can be cytotoxic, as these complexes appear incompatible with the physiological environment *in vivo* which is rich in anionic molecules. Liposomes are preferentially phagocytosed into the reticuloendothelial system. However, the reticuloendothelial system can be circumvented by several methods including saturation with large doses of liposome particles, or selective macrophage
20 inactivation by pharmacological means. Classen *et al.*, (1984) *Biochim. Biophys. Acta* 802: 428. In addition, incorporation of glycolipid- or polyethylene glycol-derivatised phospholipids into liposome membranes has been shown to result in a significantly reduced uptake by the reticuloendothelial system. Allen *et al.*, (1991) *Biochim. Biophys. Acta* 1068: 133; Allen *et al.*, (1993) *Biochim. Biophys. Acta* 1150: 9.

25 Cationic liposome preparations can be made by conventional methodologies. See, for example, Felgner *et al.*, *Proc. Nat'l Acad. Sci USA* 84:7413 (1987); Schreier, *J. of*

Liposome Res. 2:145 (1992); Chang *et al.* (1988), *supra*. Commercial preparations, such as Lipofectin® (Life Technologies, Inc., Gaithersburg, Maryland USA), also are available. The amount of liposomes and the amount of DNA can be optimized for each cell type based on a dose response curve. Felgner *et al.*, *supra*. For some recent reviews on methods employed
5 see Wassef *et al.*, *Immunomethods* 4: 217 - 222 (1994) and Weiner, A. L., *Immunomethods* 4: 217 - 222 (1994).

Other suitable liposomes that are used in the methods of the invention include multilamellar vesicles (MLV), oligolamellar vesicles (OLV), unilamellar vesicles (UV), small unilamellar vesicles (SUV), medium-sized unilamellar vesicles (MUV), large unilamellar
10 vesicles (LUV), giant unilamellar vesicles (GUV), multivesicular vesicles (MVV), single or oligolamellar vesicles made by reverse-phase evaporation method (REV), multilamellar vesicles made by the reverse-phase evaporation method (MLV-REV), stable plurilamellar vesicles (SPLV), frozen and thawed MLV (FATMLV), vesicles prepared by extrusion
methods (VET), vesicles prepared by French press (FPV), vesicles prepared by fusion (FUV),
15 dehydration-rehydration vesicles (DRV), and bubblesomes (BSV). The skilled artisan will recognize that the techniques for preparing these liposomes are well known in the art. See COLLOIDAL DRUG DELIVERY SYSTEMS, vol. 66 (J. Kreuter, ed., Marcel Dekker, Inc. 1994).

2. Suitable Adjuvants and Excipients

The present vaccine formulations, liposomal or not, may be formulated
20 advantageously with some type of adjuvant. As conventionally known in the art, adjuvants are substances that act in conjunction with specific antigenic stimuli to enhance the specific response to the antigen. MPLA, for example, has been shown to serve as an effective adjuvant to cause increased presentation of liposomal antigen by the APCs to specific T
Lymphocytes. Alving, C.R. 1993. *Immunobiol.* 187:430-446. Moreover, the skilled artisan
25 will recognize that other such adjuvants, such as Detox, alum, QS21, complete and/or incomplete Freund's adjuvant, MDP, LipidA and derivatives thereof, are also suitable.

Another class of adjuvants include stimulatory cytokines, such as IL-2. Thus, the present vaccines may be formulated with IL-2 or IL-2 may be administered separately for optimal antigenic response. IL-2 is beneficially formulated with liposomes.

Vaccines may also be formulated with a pharmaceutically acceptable excipient.

5 Such excipients are well known in the art, but typically should be physiologically tolerable and inert or enhancing with respect to the vaccine properties of the inventive compositions. Examples include liquid vehicles such as sterile, physiological saline. When using an excipient, it may be added at any point in formulating the vaccine or it may be admixed with the completed vaccine composition.

10 Vaccines may be formulated for multiple routes of administration. Specifically preferred routes include intramuscular, percutaneous, subcutaneous, or intradermal injection, aerosol, oral or by a combination of these routes, at one time, or in a plurality of unit dosages. Administration of vaccines is well known and ultimately will depend upon the particular formulation and the judgement of the attending physician.

15 Vaccine formulations can be maintained as a suspension, or they may be lyophilized and hydrated later to generate a useable vaccine.

D. Targeting the Inventive Antigens and Vaccines

In order to provide greater specificity, thus reducing the risk of toxic or other unwanted effects during *in vivo* administration, it is advantageous to target the inventive
20 compositions to the cells through which they are designed to act, namely antigen-presenting cells. This may conveniently be accomplished using conventional targeting technology. One exemplary form of targeting using antibodies, or similar specifically-binding molecules, associated in some fashion with the antigen and/or vaccine composition.

25 Targeting molecules have the characteristic of being able to distinguish to some degree, target APCs over background, non-APCs. Targeting molecules include mannose and the Fc portion of antibodies, and the like, which will target antigen presenting

cells. Targeting molecules may be directly associated with telomerase antigens, for example, by chemical conjugation or by fusion protein production, in the case of protein-based targeting sequences.

Due to their convenience and extensive familiarity in the art, antibodies and antibody derivatives are preferred targeting molecules. Antibodies and their derivatives include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies including single chain Fv (scFv) fragments, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, epitope-binding fragments, and humanized forms of any of the above. Of course, the smaller versions of these molecules are preferred, based on the fact that they will more readily target to an APC.

In general, techniques for preparing polyclonal and monoclonal antibodies as well as hybridomas capable of producing the desired antibody are well known in the art (Campbell, A.M., *Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St. Groth et al., *J. Immunol. Methods* 35:1-21 (1980); Kohler and Milstein, *Nature* 256:495-497 (1975)), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., *Immunology Today* 4:72 (1983); Cole et al., in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985), pp. 77-96). Affinity of the antisera for the antigen may be determined by preparing competitive binding curves, as described, for example, by Fisher, Chap. 42 in: *Manual of Clinical Immunology*, second edition, Rose and Friedman, eds., Amer. Soc. For Microbiology, Washington, D.C. (1980).

Fragments or derivatives of antibodies include any portion of the antibody which is capable of binding an APC target molecule, typically a surface antigen. Antibody fragments specifically include F(ab')₂, Fab, Fab' and Fv fragments. These can be generated from any class of antibody, but typically are made from IgG or IgM. They may be made by conventional recombinant DNA techniques or, using the classical method, by proteolytic

digestion with papain or pepsin. See CURRENT PROTOCOLS IN IMMUNOLOGY, chapter 2, Coligan *et al.*, eds., (John Wiley & Sons 1991-92).

F(ab')₂ fragments are typically about 110 kDa (IgG) or about 150 kDa (IgM) and contain two antigen-binding regions, joined at the hinge by disulfide bond(s). Virtually all, if not
5 all, of the Fc is absent in these fragments. Fab' fragments are typically about 55 kDa (IgG) or about 75 kDa (IgM) and can be formed, for example, by reducing the disulfide bond(s) of an F(ab')₂ fragment. The resulting free sulfhydryl group(s) may be used to conveniently conjugate Fab' fragments to other molecules, such as telomerase antigens or adjuvant molecules.

Fab fragments are monovalent and usually are about 50 kDa (from any source). Fab
10 fragments include the light (L) and heavy (H) chain, variable (V_L and V_H, respectively) and constant (C_L C_H, respectively) regions of the antigen-binding portion of the antibody. The H and L portions are linked by one or more intramolecular disulfide bridges.

Fv fragments are typically about 25 kDa (regardless of source) and contain the variable regions of both the light and heavy chains (V_L and V_H, respectively). Usually, the V_L and
15 V_H chains are held together only by non-covalent interactions and, thus, they readily dissociate. They do, however, have the advantage of small size and they retain the same binding properties of the larger Fab fragments. Accordingly, methods have been developed to crosslink the V_L and V_H chains, using, for example, glutaraldehyde (or other chemical crosslinkers), intermolecular disulfide bonds (by incorporation of cysteines) and peptide linkers. The resulting Fv is now a single chain
20 (*i.e.*, scFv).

Other antibody derivatives include single chain antibodies (U.S. Patent 4,946,778; Bird, Science 242:423-426 (1988); Huston *et al.*, Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward *et al.*, Nature 334:544-546 (1989)). Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single
25 chain FV (scFv).

Derivatives also include "chimeric antibodies" (Morrison *et al.*, Proc. Natl. Acad. Sci., 81:6851-6855 (1984); Neuberger *et al.*, Nature, 312:604-608 (1984); Takeda *et al.*,

Nature, 314:452-454 (1985)). These chimeras are made by splicing the DNA encoding a mouse antibody molecule of appropriate specificity with, for instance, DNA encoding a human antibody molecule of appropriate specificity. Thus, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Recombinant molecules having a human framework region and murine complementarity determining regions (CDRs) also are made using well-known techniques. These are also known sometimes as "humanized" antibodies and they and chimeric antibodies or antibody fragments offer the added advantage of at least partial shielding from the human immune system. They are, therefore, particularly useful in therapeutic *in vivo* applications.

E. Nucleic Acid-Based Vaccines

Recently, there has been increased interest in polynucleotide-based vaccines, and such applications are contemplated here. These vaccines generally rely on either a DNA vector that encodes the antigen of interests under operable control of transcription and translation signals, or a RNA vector that encodes the antigen of interests under operable control of translation signals. When these vaccines are administered, they are thought to be taken up by the surrounding cells, which then express the target antigen. The expressed antigen apparently becomes associated with the cell's major histocompatibility (MHC) antigens and are thus localized to the surface of the cell and presented to immune cells. See, for example, Corr *et al.*, *J. Exp. Med.* 184: 1555-60 (1996). Such vaccines may employ naked DNA (*Id.*) or the DNA may be liposomally associated or trapped (Gregoriadis *et al.*, *FEBS Lett.* 402: 107-10 (1997)).

These so-called "naked DNA" vaccines or vaccines comprising RNA have broad applicability. They may be employed, for example, as anti-cancer vaccines (Scheurs *et al.*, *Cancer Res.* 58: 2509-14 (1998); Hurpin *et al.*, *Vaccine* 16: 208-15 (1998)) and anti-viral vaccines (Bohm *et al.*, *Vaccine* 16: 949-54 (1998); Lekutis *et al.*, *J. Immunol.* 158: 4471-77 (1997)), among others. Naked DNA vaccines have been shown to elicit both class I- (Scheurs

, *et al.*, *supra*; Bohm *et al.*, *supra*; Hurpin *et al.*, *supra*) and class II-restricted responses (Lekutis *et al.*, *supra*; Manickan *et al.*, J. Leukoc. Biol. 61: 125-32 (1997))).

Accordingly, any of the foregoing telomerase antigens may be administered as a naked DNA vaccine. These vaccines will comprise a nucleic acid vector that encodes a
5 telomerase antigen under the control of transcription and translation signals that operate in a mammal, preferably a human. They may be administered associated with or encapsulated by (usually cationic) liposomes, as detailed above, or they may be administered in any other physiologically tolerable excipient.

F. Methods of the Invention

10 According to one aspect of the invention, the foregoing telomerase antigens (or vaccine compositions) may be used as a conventional vaccine directly to induce an immune response against telomerase. In some cases, however, for an improved therapeutically or prophylactically suitable T-cell response, the antigen may be liposome-associated, as indicated above.

15 Since telomerase is expressed at high levels in cancer cells, the present antigens and vaccines are particularly suited for methods of treating and/or preventing cancer. A representative method involves administering to a cancer patient an effective amount of one or more of the foregoing telomerase antigens, which may be formulated as a vaccine. Again, smaller peptide antigens are preferred.

20 In addition, it is contemplated that the present telomerase antigens and vaccines will be particularly useful in *ex vivo* techniques. In general, these techniques entail isolating cells from a patient, contacting them with a telomerase antigen (or a vaccine, including nucleic acid vaccines) and administering the contacted cells back to the patient. In some cases (subject, for example, to MHC matching) the cells may be taken from one patient
25 for administration to another.

In one embodiment, autologous or compatible antigen presenting cells (usually dendritic cells or peripheral blood lymphocytes) are primed *ex vivo*, with a telomerase antigen. These "telomerase-primed" cells may then be transferred in beneficial amounts into a patient in need of therapy or prophylaxis. As with all aspects of the invention, the *ex vivo* priming
5 step may be accomplished using lipid- and or liposome-associated small peptide antigen.

Yet another adoptive approach is contemplated, whereby antigen presenting cells are generated, as above, and used to generate autologous or compatible T-cells effectors *ex vivo*. T-cells so generated may be adoptively transferred in beneficial amounts to a patient in need. For a description of art-recognized techniques for adoptive T-cell transfer therapy,
10 see Bartels, *et al.* Annals of Surgical Oncology, 3(1):67 (1996), which is hereby incorporated by reference.

Co-treatment with other immunostimulatory, listed above, is also contemplated. Molecules like IL-2, GM-CSF, IL-12, flt-3 ligand, CD 40, and the like, are envisioned as quite useful. IL-2, for example, may be administered concurrently, separately
15 or in a combined formulation, or it may be administered in an alternative dosing regime with the telomerase antigen or vaccine. In a one method, the IL-2 is formulated with liposomes.

In a further embodiment of the invention, any of the foregoing antigens or vaccines may be used in conjunction with known anti-cancer agents. One example includes MUC-1-based therapeutics. Numerous additional examples of these are well-known in the art
20 Conventional chemotherapeutic agents include alkylating agents, antimetabolites, various natural products (*e.g.*, vinca alkaloids, epipodophyllotoxins, antibiotics, and amino acid-depleting enzymes), hormones and hormone antagonists. Specific classes of agents include nitrogen mustards, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogues, pyrimidine analogues, purine analogs, platinum complexes, adrenocortical suppressants,
25 adrenocorticosteroids, progestins, estrogens, antiestrogens and androgens. Some exemplary compounds include cyclophosphamide, chlorambucil, methotrexate, fluorouracil, cytarabine, thioguanine, vinblastine, vincristine, doxorubicin, daunorubicin, mitomycin, cisplatin,

hydroxyurea, prednisone, hydroxyprogesterone caproate, medroxyprogesterone, megestrol acetate, diethyl stilbestrol, ethinyl estradiol, tomosifen, testosterone propionate and fluoxymesterone.

5 A therapeutically or prophylactically beneficial or effective amount is an amount sufficient to induce a clinically relevant telomerase-specific T-cell response, as defined above. Clinical relevance can be determined by clinician.

Administration may be by any number of routes, including parenteral and oral. Cell-based vaccines are advantageously administered intravenously. Other vaccines typically will be administered intramuscularly, intradermally, subcutaneously or orally. The skilled
10 artisan will recognize that the route of administration will vary depending on the nature of the vaccine formulation. Determining the optimal route of vaccination may be determined empirically and is well within the level of ordinary skill in the art.

Nucleic acid vaccines may also be administered by a variety of routes, the optimal route being determined empirically. For instance, some antigens have been found to
15 elicit a superior cytotoxic response when administered intravenously. Hurpin *et al*, *supra*. For a superior immune response to oral administration, it may be advantageous to co-administer with the vaccine a mucosal adjuvant, like cholera toxin or cationic lipids. Ethchart *et al.*, J. Gen. Virol. 78: 1577-80 (1997). Intramuscular, intradermal and subcutaneous administration are also preferred.

20

EXAMPLES

EXAMPLE 1

This example illustrates the use of the telomerase-specific peptides to generate an antigen-specific cytotoxic T-cell response.

A. Materials and Methods

In general, PCT/US98/09288; Agrawal *et al.*, Int'l Immunol.10:1907-16 (1998); and Agrawal *et al.*, Cancer Res. 55:5151-56 (1998) provide suitable methods, and those disclosures are hereby incorporated by reference, in their entirety.

Peptides. Peptides were selected using the HLA peptide search program at
5 <http://www-bimas.dcrn.nih.gov>. HLA-A2 specificity was selected, with default parameters. Three of the top twenty scores were synthesized and tested. These peptides has the sequences: RLVDDFLV, ELLRSFFYV and ILAKFLHWL.

Preparation of Liposomes. The bulk liquid composition of liposomes consisted of dipalmitoyl phosphatidyl choline (DPPC), cholesterol (Chol) and dimyristoyl phosphatidyl
10 glycerol (DMPG) in a molar ratio of 3:1:0.25 and contained Lipid A at a concentration of 1% (w/w) of bulk lipid. Synthetic telomerase peptides were present in the aqueous phase during liposome formation at a concentration of 0.7 mg/ml, and approximately 28% of the input peptide was captured within the liposome structures. The formulated product contained 2 mg of bulk lipid, 20 µg Lipid A and about 20 µg of peptide per injected dose of 100 µl.

15 Bulk lipids and Lipid A were dissolved in chloroform/methanol (methanol was used initially to solubilize DMPG). The lipid mixture for each 4 ml preparation of liposomes consisted of 64 mg DPPC, 11 mg Chol, 5 mg DMPG, 0.8 mg Lipid A in 12 ml of chloroform/methanol in a molar ratio of 3:1:0.25 at a final lipid concentration of 30 mM. Each 12 ml of the lipid mixture was dried to a film by rotary evaporation at 53°C in a 250 ml round
20 bottom flask, and residual solvent was removed under high vacuum. The lipid film was hydrated by addition of 4 ml PBS containing the peptide and slow rotation of the flasks at 53°C followed by 5 cycles of vortexing and warming to 53°C.

Liposome structures were reformed to a more uniform size by a series of 5 freeze/thaw cycles consisting of freezing in a dry ice bath, thawing, warming to 41°C and
25 vortexing before beginning the next cycle. Liposomes then were collected by

ultracentrifugation at 1500,000 x g at 4°C for 20 minutes, washed twice by addition of PBS and ultracentrifugation again. Liposomes were finally reconstituted to the desired volume.

Cytokines. In order to promote CTL generation, human recombinant cytokines, IL-12 (R&D Systems, Minneapolis, MN), IL-7 (Intermedico, Markham, Ontario) were diluted in serum-free AIM-V media (Life Technologies) just prior to use.

General Procedures for Loading APCs with Liposome-encapsulated peptide. Human peripheral blood lymphocytes (PBLs) were purified from heparinized blood by centrifugation in Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). The Ficoll-blood interface layer obtained by centrifugation was collected and washed twice with RPMI before use.

Briefly, to 2-10x10⁶ PBLs in 0.9 mL AIM-V media, one dose of liposome containing peptide formulation was added and the PBLs were incubated overnight at 37°C with CO₂ supplemented incubator. After incubation, the PBLs were treated with mitomycin C or γ-irradiated (3000 rads) followed by washing with AIM-V media.

Cytotoxic T lymphocyte assays. For the CTL assay, three (HLA.A2*) normal donors' PBLs were used. The T-cells were grown for five weeks in bulk cultures as described above. At the end of two weeks, live T-cells were harvested from flasks and counted. The targets were mutant T2 cells. Houbiers *et al.*, Eur. J. Immunol 23:2072-2077 (1993); Stauss *et al.*, Proc. Natl. Acad. Sci. U.S.A. 89:7871-7875 (1992). The telomerase peptide-mediated upregulation of HLA.A2 expression on T2 cells was examined using the HLA-A2-associated peptides ILAKFLHWL (BP1-187), RLVDDFLLV (BP1-190), and ELLRSFFYV (BP1-191) using known methods. Townsend *et al.*, Nature 346:476 (1989). T2 cells were loaded overnight at 37°C in 7% CO₂ with various the telomerase synthetic peptides at 200 μM in presence of 8 μg exogenous β2 microglobulin. Houbiers *et al.*, *supra*; Stauss *et al.*, *supra*. The peptide-loaded T2 target cells were loaded with ⁵¹Cr (using NaCrO₄) for 90 minutes and washed. CTL assays were performed as previously described. Agrawal *et al.*, J. Immunol. 156:2089 (1996). Percent specific killing was calculated as: experimental release -

spontaneous release/maximum release - spontaneous release x 100. The effector versus target ratios used were 50:1, 25:1, 10:1 and 5:1. Each group was set up in four replicate and mean percent specific killing was calculated.

Cell Surface Immunofluorescence Staining. For detection of cell surface

5 antigens, the peptide-fed T2 cells were washed once in cold PBS containing 1% BSA followed by addition of 1 µg of anti-A2 monoclonal antibody, MA2.1 or a control antibody and incubated for 45 minutes on ice. Cells were then washed and a secondary antibody, goat anti-mouse IgG (H+L)-FITC labeled (Southern Biotech) was added for 30 minutes on ice.

B. Results

10 Using the foregoing methods, the cytotoxic activity of T-cells stimulated with autologous APCs pulsed with liposomal telomerase peptide was determined. The source of T-cells was PBLs from three HLA.A2⁺ donors. Target T2 cells (HLA.A2⁺) were loaded with the telomerase peptide indicated above.

The negative control was T2 cells, and the positive control was the 10-mer flu
15 peptide FLPSDYFPSV, which strongly upregulates HLA.A2 expression on T2 cells. These data confirm that the present methods can be used to generate specific, biologically relevant T-cell responses to telomerase, such as cytotoxicity.

Figure 1 shows FACS analysis of cells treated according to the foregoing methods, panel A shows the negative control. Panel B, is the positive control, showing a
20 227% increase in median channel intensity of A2 expression as compared to the negative control. Panel C, is the experimental with BP1-187, and shows a 396% increase in median channel intensity of A2 expression as compared to the negative control. Panels D and E show the results with BP1-190 and BP1-191, respectively yielding 0% and 6% increases over the negative control.

25 Table I shows specific killing of targets by telomerase antigen-primed (BP1-187) cytotoxic T-cells. The negative control was SIINFEKL.

These data indicate that, contrary to expectations, an immune response can be generated against telomerase, a self-antigen.

Table I: Telomerase Peptide-Specific Killing

TARGET	EFFECTOR:TARGET RATIO	PERCENT KILLING
Unloaded	50:1	35.7
Unloaded	25:1	23.8
Unloaded	10:1	13.1
Unloaded	5:1	5.0
Telomerase Peptide-Loaded	50:1	56.7
Telomerase Peptide-Loaded	25:1	33.5
Telomerase Peptide-Loaded	10:1	21.1
Telomerase Peptide-Loaded	5:1	15.5
Control Peptide-Loaded	50:1	32.3
Control Peptide-Loaded	25:1	22.1
Control Peptide-Loaded	10:1	11.3
Control Peptide-Loaded	5:1	7.6

- The foregoing detailed description and examples are presented for illustrative
- 5 purposes only and are not meant to be limiting. Further embodiments of the invention will be ready apparent to the skilled worker in view of this disclosure.

What Is Claimed Is:

1. A peptide, comprising less than about 60 amino acids of the native telomerase protein sequence, optionally having one or more conservative substitutions, wherein said peptide is capable of binding at least one human leukocyte antigen (HLA).
2. A peptide according to claim 1, wherein said HLA molecule is a class I molecule.
3. A peptide according to claims 1 or 2 which is about 8 to about 12 amino acids in length.
4. A peptide according to any of claims 1, 2 or 3, comprising the sequence ILAKFLHWL, or a conservative variant thereof.
5. A vaccine, comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, and a lipid, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA).
6. A vaccine according to claim 5, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
7. A vaccine according to claims 5 or 6, wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.
8. A vaccine according to any of claims 5, 6 or 7, wherein said lipid is part of a liposome.
9. A method of treating or preventing cancer, comprising administering to a patient in need thereof an effective amount of a composition which comprises at least a portion of the native telomerase protein sequence, optionally having one or more conservative

amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said portion is capable of binding at least one human leukocyte antigen (HLA).

10. A method according to claim 9, wherein said composition further comprises a lipid.

11. A method according to claims 9 or 10, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.

12. A method according to any of claims 9, 10 or 11, wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.

13. A method according to any of claims 10, 11 or 12, wherein said lipid is part of a liposome.

14. A method of treating or preventing cancer, comprising administering to a patient in need thereof a telomerase-primed antigen-presenting cell.

15. A method according to claim 14, wherein said antigen-presenting cell is primed using a composition comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA).

16. A method according to claim 15, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.


17. A method according to claim 16, wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.

18. A method according to any of claims 15, 16 or 17, wherein the composition further comprises a lipid.

19. A method according to claim 18, wherein said lipid is in a liposome.
20. A method according to any of claims 14-19, further comprising administering an effective amount of interleukin-2 (IL-2) to said patient.
21. An isolated polynucleotide that encodes a telomerase specific antigen, wherein said polynucleotide is less than about 180 nucleotides in length.
22. A polynucleotide according to claim 21 which is about 24 to about 36 nucleotides in length.
23. A polynucleotide according to claims 21 or 22, wherein said antigen is a class I-specific antigen.
24. A polynucleotide according to any of claims 21, 22 or 23, which encodes a peptide comprising the sequence ILAKFLHWL, or a conservative variant thereof.
25. A method of producing a telomerase-primed antigen-presenting cell, comprising contacting an antigen-presenting cell with a composition comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA).
26. A method according to claim 25, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
27. A telomerase-primed antigen-presenting cell which is produced according to claim 25 or 26.
28. A peptide according to claim 2 which is less than about 25 amino acids in length.



29. A polynucleotide according to claim 21 which is less than 75 nucleotides in length.
30. Use of a composition comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA), for treating or preventing cancer.
31. A use according to claim 30, wherein said composition further comprises a lipid.
32. A use according to claim 31, wherein said lipid is part of a liposome.
33. A use according to any of claims 30-32, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
34. A use according to any of claims 30-33, wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.
35. Use of a telomerase-primed antigen-presenting cell for treating or preventing cancer.
36. A use according to claim 35, wherein the antigen-presenting cell is primed using a composition comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA).
37. A use according to claim 36, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
38. A use according to claims 36 or 37, wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.

39. A use according to any of claims 36-38, wherein the composition further comprises a lipid.
40. A use according to claim 39, wherein said lipid is in a liposome.
41. Use of a composition comprising a telomerase-primed antigen-presenting cell according to any of claims 15-19, wherein the composition further comprises interleukin-2 (IL-2), for treating or preventing cancer.

**FIG. 1**

SUBSTITUTE SHEET (RULE 26)

2/2

**FIG. 1 CONT.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 October 2000 (19.10.2000)

PCT

(10) International Publication Number
WO 00/61766 A3

(51) International Patent Classification⁷: **C12N 15/54**,
9/12, A61K 38/45, 9/127, C12N 5/08 // A61P 35/00

(74) Agent: **RUDOLPH, John, R.; BERESKIN & PARR**, 40
King Street West, Box 401, Toronto, Ontario M5H 3Y2
(CA).

(21) International Application Number: **PCT/IB00/00610**

(22) International Filing Date: **7 April 2000 (07.04.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/128,539 **9 April 1999 (09.04.1999)** **US**

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US **60/128,539 (CIP)**
Filed on **9 April 1999 (09.04.1999)**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
BIOMIRA, INC. [CA/CA]; 2011 - 94th Street, Ed-
monton, Alberta T6N 1H1 (CA).

Published:

— *With international search report.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **AGRAWAL, Babita**
[IN/CA]; 732 Revell Crescent, Edmonton, Alberta T6R
2E8 (CA). **LONGENECKER, Bryan, Michael [CA/CA]**;
440 Rooney Crescent, Edmonton, Alberta T6R 1C8 (CA).

(88) Date of publication of the international search report:
8 March 2001

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **TELOMERASE-SPECIFIC CANCER VACCINE**

(57) Abstract: Telomerase-specific T-cell antigens are provided, which are useful in generating T-cell responses against telomerase. Formulations of telomerase antigens as vaccines are useful in treating and preventing cancer, using *in vivo* or *ex vivo* techniques.

WO 00/61766 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 00/00610

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/54 C12N9/12 A61K38/45 A61K9/127 C12N5/08
//A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VONDERHEIDE R H ET AL: "Search for universal tumor antigens: Potential of the catalytic telomerase subunit." BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), page 500A XP000971197 ISSN: 0006-4971	1-3,9, 11,12, 21-23, 28-30, 33,34
Y	the whole document & 40th Annual Meeting of the American Society of Hematology; Miami Beach, Florida, USA; December 4-8, 1998 --- -/--	5-20, 25-27, 30-41

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

8 December 2000

Date of mailing of the international search report

21/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 00/00610

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 50527 A (LONGENECKER B MICHAEL ;BIOMIRA INC (CA); KRANTZ MARK J (CA); AGRAW) 12 November 1998 (1998-11-12) cited in the application the whole document	5-20, 25-27, 30-41
A	WO 98 14592 A (UNIVERSITY TECHNOLOGY CORP., USA;GERON CORP.) 9 April 1998 (1998-04-09) page 61 example 17 figure 57	1-41
A	GAGLIARDI M C ET AL: "Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro" INTERNATIONAL IMMUNOLOGY, vol. 7, 1995, pages 1741-1752, XP002078855 ISSN: 0953-8178	
P,X	WO 00 02581 A (NORSK HYDRO ASA, NORWAY) 20 January 2000 (2000-01-20) page 8, paragraph 3 -page 9 page 12 -page 17, line 6 claims	1-4,9, 11,12, 14-17, 20-30, 33-38,41
P,X	VONDERHEIDE R H ET AL: "THE TELOMERASE CATALYTIC SUBUNIT IS A WIDELY EXPRESSED TUMOR- ASSOCIATED ANTIGEN RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES" IMMUNITY, vol. 10, no. 6, June 1999 (1999-06), pages 673-679, XP000890114 ISSN: 1074-7613 the whole document	1-4,9, 11,12, 14-17, 20-30, 33-38,41
P,X	WO 99 50392 A (GERON CORP ;GAETA FEDERICO C A (US)) 7 October 1999 (1999-10-07) page 2, line 18 -page 3 page 7, line 20 -page 16, line 16	1-3,9, 14-17, 20, 25-30, 33-38,41
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/00610

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 00 25813 A (DANA-FARBER CANCER INSTITUTE, USA; WHITEHEAD INSTITUTE FOR BIOMEDICAL R) 11 May 2000 (2000-05-11)</p> <p>page 2, line 18 -page 5</p> <p>page 49, line 13 -page 50</p> <p>page 58, line 9 -page 65, line 21</p> <p>page 81 -page 95</p> <p>claims</p>	1-41
T	<p>MINEV BORIS ET AL: "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans."</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES,</p> <p>vol. 97, no. 9,</p> <p>25 April 2000 (2000-04-25), pages 4796-4801, XP002155017</p> <p>ISSN: 0027-8424</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/00610

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9850527 A	12-11-1998	AU 7371298 A EP 0986636 A	27-11-1998 22-03-2000
WO 9814592 A	09-04-1998	US 6093809 A AU 4803697 A AU 4807397 A BR 9711844 A BR 9712254 A CH 689672 A CN 1254376 A DE 19743497 A DE 841396 T EP 0841396 A EP 0932686 A EP 0954585 A FI 990655 A FR 2757177 A GB 2317891 A,B GB 2321642 A,B JP 11313689 A JP 10234384 A JP 11253177 A NO 991588 A WO 9814593 A	25-07-2000 24-04-1998 24-04-1998 18-01-2000 18-01-2000 13-08-1999 24-05-2000 20-08-1998 24-09-1998 13-05-1998 04-08-1999 10-11-1999 24-03-1999 19-06-1998 08-04-1998 05-08-1998 16-11-1999 08-09-1998 21-09-1999 31-05-1999 09-04-1998
WO 0002581 A	20-01-2000	NO 983141 A AU 4534099 A	10-01-2000 01-02-2000
WO 9950392 A	07-10-1999	AU 3456099 A	18-10-1999
WO 0025813 A	11-05-2000	AU 1331100 A	22-05-2000

THIS PAGE BLANK (USPTO)